Investigational drug · Phase 3
NRT6003
Also called: Yttrium-90 carbon microspheres
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NRT6003"
First trial start
2025
Apr 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NRT6003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NRT6003" as an intervention, largest first.
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSpherePivotal-lookingActive, not recruiting
Chengdu New Radiomedicine Technology Co. LTD.Industry
NCT06900543 · 108 participants (planned) · Start Apr 15, 2025 · Primary completion Oct 2027
Drug: NRT6003 Injection; cTACE · For: Unresectable Hepatocellular Carcinoma
Sites: Fuzhou, China; Guangzhou, China; Zhengzhou, China · 19 sites in all
Chengdu New Radiomedicine Technology Co. LTD.Industry
NCT06310590 · 40 participants · Start Aug 8, 2023 · Primary completion Jun 10, 2025
Drug: NRT6003 Injection · For: Unresectable Hepatocellular Carcinoma
Sites: Hefei, China; Guangzhou, China; Zhengzhou, China · 10 sites in all
- Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular CarcinomaNot yet recruiting
Second Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT07657273 · 20 participants (planned) · Start Jun 22, 2026 · Primary completion Dec 21, 2027
Drug: NRT6003 Injection · For: Hepatocellular Carcinoma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Unresectable Hepatocellular Carcinoma
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.